Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural...

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Oxytocin (OXT) is an endogenous neuropeptide vital for social behavior and emotional processing.
• Intranasal OXT delivery is common in clinical research for psychiatric disorders, but results are mixed due to limited pharmacokinetic/pharmacodynamic models.
• OXT's mechanism of reducing neural activation in emotional response areas suggests potential for conditions like youth irritability.

Purpose of the Study:

• To review randomized controlled trials (RCTs) of intranasal OXT in pediatric patients with Autism Spectrum Disorder (ASD), Prader-Willi Syndrome (PWS), or Phelan-McDermid Syndrome (PMS).
• To assess the impact of intranasal OXT on irritability and related neural mechanisms in these pediatric populations.
• To identify areas for future research regarding OXT's efficacy, dosing, and safety in pediatric psychopathology.

Main Methods:

• Mini-review of fifteen randomized controlled trials (RCTs).
• Focus on pediatric patients diagnosed with ASD, PWS, or PMS.
• Analysis of reported changes in irritability, adverse events, and neuroimaging findings.

Main Results:

• Most studies featured small sample sizes and varied OXT dosages.
• Irritability changes were frequently noted as adverse events.
• Neuroimaging revealed OXT's modulation of reward processing and social-emotional neural networks.

Conclusions:

• Intranasal OXT may modulate neural systems involved in social-emotional processing, with potential implications for youth irritability.
• Current research is limited by small sample sizes and inconsistent methodologies.
• Further investigation is crucial to establish optimal OXT dosing, duration, target populations, and safety profiles for clinical application.